Víctor Manuel Vargas-Aguilar

Management of recurrent epithelial ovarian cancer

Epithelial ovarian cancer is the fifth most common cancer in women. It is usually diagnosed at an advanced stage and is the leading cause of death from gynecologic cancers in women. The overall survival rate at five years is 50% and its treatment is still poor. We need new treatments for patients with recurrent ovarian cancer who are incurable with current management. We review the effectiveness of new biological agents and morbidity and mortality of cytoreductive surgery. Since the hyperthermic increases the effectiveness of chemotherapy and the chance of survival, hyperthermic intraperitoneal chemotherapy has been proven to be a promising option, however it still requires further study to be the standard treatment.

Metabolic syndrome in breast cancer

Breast Cancer is a heterogeneous disease, progressive, currently, are classified according to in pattern of gene expression luminal A, luminal B, basal and HER-2neu + and Triple-negative, 75% to 80% have receptors positive hormonal and 15% to 20% are positive for hER-2neu and 10% to 20% are triple negative, with hormone receptor negative and HER2-neu and their diagnostic is made by exclusion, the Metabolic Syndrome is related to a higher incidence of these cancers where the insulin-leptin axis-adiponectin are implicated in carcinogenesis.

Ovary Cancer: Surgical Techniques and Innovative Treatments

Globally, in 2008 epithelial ovarian cancer (EOC) were diagnosed in 225,000 women, 140,000 deaths from this disease. EOC is the fifth most common cancer in women and the fourth most common cause of cancer death in women with a lifetime risk o 1 in 54 to develop. In developing countries, is the third (after cervical cancer, which is the most common) most common gynecologic malignancy, with an incidence of 5 per 100,000, and the mortality rate of 3.1 per 100,000. The EOC is the second most common gynecologic cancer and the leading cause in the United States of North America, where every year 21,980 new cases and 14,270 deaths. It is usually diagnosed at an advanced stage, diagnosed in stages 15 % localized, regional 18 % and distant 61 %, with most between 60 and 79 years, representing 5 % of all cancer deaths from ginecological cancer in women. Overall survival rate at 5 years is 50 % and its treatment remains poor.